Why founders use this directory
- 34
- Active biotech VC firms in this list
- 10,000+
- Total investors in Round Funded
- 12
- Languages supported
- Free
- No credit card required
Round Funded
Active biotech-focused investors 2026
Each name is a real VC firm with a clear biotech thesis. Click any row, LinkedIn icon, or website link to start your outreach.
Round Funded unlocks 10,000+ active investors across stages and geographies.
Round Funded
Free investor directory
Top biotech investors and venture capital firms in 2026
The most active biotech investors writing checks right now. Hand-verified. Updated every quarter.
Get the full list of biotech investors 2026
All names, their funds, focus areas, LinkedIn profiles, and websites. Plus 10,000+ more active investors across stages and industries inside Round Funded.
- Hand-verified biotech investors writing checks in the last 12 months
- Real photos, websites, and LinkedIn profiles in one place
- Free. No credit card. No paywall on the names.
Used by founders raising from YC, Techstars, 500, Antler, and Google for Startups.
Created by founders from top global accelerators
How this list is built
We do the research so you do not have to. Three signals tell us a biotech investor is worth your time.
- 01
Public investment activity in last 12 months
We track Crunchbase, SEC Form D filings, and public deal announcements. Only biotech investors with at least one announced check in the last year make the list.
- 02
Real public presence
Every entry has a verifiable website and LinkedIn profile. No anonymous LP money, no defunct funds.
- 03
Updated quarterly
We re-verify this list every three months against fresh data. Inactive funds get removed. New active ones get added.
How to reach a biotech investor in 2026
Outreach to biotech investors works when the email is sharp and the timing is right. Four things every biotech investor checks before replying.
01
Lead with the science, not the market
Biotech VCs are scientists. They want to see your mechanism of action, your differentiation against existing drugs, and your preclinical data first. Market size and TAM come second.
02
Match the firm's modality
Biotech firms specialize. Some only do small molecules, some only do cell and gene therapy, some only do diagnostics or devices. Read each firm's portfolio before reaching out.
03
Show real preclinical data
A 1-page slide of your strongest preclinical result is worth more than 30 slides of mechanism. Biotech VCs want signal that the science works, not a story about why it should.
04
Be honest about timeline and capital
Biotech founders who overpromise on timeline and underestimate capital needs lose credibility fast. Quote realistic preclinical and clinical milestones and the dollars needed to reach them.
Frequently asked questions
Are these biotech VC firms actually active in 2026?
Yes. Every firm on this list announced a biotech investment in the last twelve months and has biotech, life sciences, or healthcare as a stated focus.
What stage are biotech VCs investing at?
It varies. Some only do seed and Series A on preclinical assets. Some only invest in clinical-stage. Some do both. Read each firm's recent investments to find the right stage fit.
Do biotech VCs invest in software-only companies?
Some do. Biotech firms increasingly back AI for drug discovery, lab automation, and clinical trial software. Look at firms that have both pure biotech and SaaS investments to find the overlap.
Will biotech VCs reply to a cold email?
Slowly. Biotech VCs are deliberate. Reply rates are 5 to 12 percent when the email leads with the science and not the team. Expect 2-3 week response times.
More fundraising resources
Keep building your investor list and your outreach.
Round Funded
Stop guessing. Start raising.
Round Funded pulls 10,000+ active investors across stages and geographies, drafts the outreach, and sends from your own Gmail. Track every open and reply in one pipeline.